

RESPIRATORY SYNCYTIAL VIRUS WITH A GENOMIC DEFICIENCY COMPLEMENTED IN TRANS

Field of the invention

5 The present invention relates to the field of vaccination, and more specifically to vaccines against disease caused by pneumoviruses such as e.g. Respiratory Syncytial Virus (RSV). The invention pertains RSV virions carrying an RSV genome in which a gene that is essential for infectivity has been inactivated, while the corresponding wild type gene-product is complemented *in trans* to the virion. The invention further relates 10 to methods for the production of such RSV virions and to their use in vaccines and methods for vaccination against pneumoviruses.

Background of the invention

15 Human respiratory Syncytial virus is classified in the genus Pneumovirus, family Paramyxoviruses. It is a major cause of severe lower respiratory tract disease in infants, the elderly and in immunocompromised individuals. It is also an important factor in upper respiratory tract disease in older children and adults. Currently there is no effective h-RSV vaccine available in the art.

20 RSV is an enveloped RNA virus that expresses two major antigens at its surface: the attachment protein G and the fusion protein F. Both proteins appear to invoke protective antibodies. G is the determinant of the two known h-RSV subgroups A and B. Antigenic differences can be found within the two groups. The G protein shows a high degree of variation with only 53 % amino acid homology between groups A and B and up to 20% differences in G protein sequences within group A (Mufson 1988, Cane 25 1991).

25 Passive immunisation with RSV-enriched immunoglobulin (Respigam) or synthetic humanised monoclonal antibodies against F (Palivizumab) is currently used to treat and protect neonates of certain predispositions (e.g. premature birth) against RSV infection (Robinson 2000, Greenough 2000). RSV pathology has two major aspects: cell damage caused by the virus itself and tissue damage caused by the overreacting immune system. The latter is a highly complicating factor in vaccine design.

RSV infections are seasonal, limited to the winter period and peak in the Northern Hemisphere around the end of the year. RSV infects every child before the age of two, in many cases twice. Older individuals on average are infected every other year, depending on the setting; people in close contact with infants and young children have a 50% risk. The virus spreads by close contact, in droplets or through contaminated surfaces. RSV is not efficiently spread through aerosols; the virus particles are relatively unstable. Internal spread of the virus from the upper respiratory tract (URT) to the lower respiratory tract (LRT) occurs predominantly by inhalation of virus particles produced in the URT epithelium during primary infection. Spread through syncytium formation (one of the pathological properties of the virus, which gave it its name) can not be ruled out and may play a secondary role in LRT infection.

In general, RSV pathology starts in the URT; the port of entry is the nose and to a lesser extent the eyes – not the mouth. When restricted to URT tissues, disease is limited to common cold, although in adults sometimes severe. However, when the virus can reach the LRT, bronchiolitis and pneumonia can ensue in unprotected individuals. In young infants, this can be life threatening, approx. 1/100 will require hospitalisation and mechanical ventilation, out of these 1% may die. In the elderly, RSV-induced LRT disease is a major cause of hospitalisation; it is suspected that RSV causes 25% of flu-like diseases.

The immune response to RSV is complex. In general, exposure to h-RSV will build up a response that protects against LRT disease. This response wanes with older age, causing the higher susceptibility to RSV of the older population. Effective long lasting protection against URT disease appears not feasible: re-infection is very common, even within the same season and this is not caused by viral variation.

Protection against RSV infection involves antibodies against viral proteins F and G circulating in the blood, which can prevent LRT disease. URT infection can be controlled by mucosal antibodies against F and G, but these have a limited life span. CD8+ T cells against as yet unidentified viral proteins are required to clear the virus from infected tissues, but they appear to be short-lived or inefficiently recruited from their reservoirs. Most likely, this is caused by RSV-expressed factors, possibly encoded in the G gene (Srikiatkachorn, 1997a).

An important aspect of RSV disease is immune enhancement of pathology. In limited cases the cellular immune response can exacerbate RSV disease by the action of

cytokines on infected tissues released from excessively attracted granulocytes. Host predisposition is involved in this reaction, but possibly also the timing of first RSV infection after birth. Unfortunately, early vaccine trials with formalin-inactivated RSV showed that in these vaccination settings immune enhanced pathology upon wt
5 infection was prevalent (Kim 1969). Factors contained in RSV appear to be responsible for this phenomenon and were apparently released by formalin treatment. In the 40 years since then, it was gradually shown that the viral G protein is the predominant mediator of these problems, but the mechanism remains unclear (Srikiatkachorn 1997b). In any case, vaccination with a G protein out of the context of the virion (i.e. in
10 inactivated virus preparations, as expression product not properly embedded in a membrane or in the form of peptides) seems to be causing immune enhancement in model systems. Thus, although G contributes to some extent to RSV immunity, its properties also complicate vaccine design.

Initial live RSV vaccine candidates included cold passaged or temperature-
15 sensitive mutants. The former have been attenuated by culturing at decreasing temperature, leading to dependency on low temperatures for growth, whereas the latter mutants have been made dependent on a specific, usually higher temperature for replication by chemical or radiation mutagenesis. These live virus vaccine candidates appeared to be either under- or overattenuated (Crowe 1998).

20 Subunit vaccine candidates are derived from either the RSV-F or the G protein, being the main targets for neutralising antibodies. A candidate subunit vaccine, PFP2, purified F protein, is safe in RSV-seropositive patients, but it did not provide full protection against LRT infection and associated disease (Gonzalez 2000). Another subunit vaccine approach is BBG2Na, which consists of a polypeptide, comprising
25 amino acid 130-230 of h-RSV-G, fused to the albumin-binding domain of streptococcal G protein (Power 1997). BBG2Na induces a T helper type 2 response in neonatal mice, and does not elicit lung immunopathology (Siegrist 1999). There is no data yet on protection. The use of new adjuvants for a balanced humoral and cellular immune response are currently under investigation in animal models (Plotnick 2003).

30 The use of plasmid-DNA vectors encoding RSV-F and G antigens as vaccine candidates has been studied in animal models. These vaccines induce protective responses in rodents (Li 2000), but in one study RSV-F DNA vaccine candidate immunised mice developed a slightly enhanced pulmonary inflammatory response

following challenge with wt virus (Bembridge 2000). The feasibility of the use of plasmid DNA vaccines in humans is not yet known and it will likely take at least 15 years before this approach is sufficiently studied and - more importantly - accepted, particularly for neonates. Candidate vaccines based on vector delivery systems are 5 constructed of live recombinant vectors expressing RSV proteins. For example, recombinant vaccinia virus expressing RSV-F and G provided protection in mice, but lacked this effect in chimpanzees (Collins 1990). The question is whether these systems are safe (notably vaccinia virus) and feasible in the light of existing (maternal) antibodies against poxviruses in the community and the main target group being 10 neonates.

Several vaccine candidates are based on recombinant live RSV, generated by reverse genetics. One line of study focuses on attenuating these viruses by introducing the individual or combined mutations responsible for cold-adaptation and temperature-sensitivity into the recombinant virus. None of these vaccine candidates were usable, 15 because of either over- or underattenuation. Another line of study focuses on deletion of one or more viral non-structural genes. Limited data are available on the behaviour of these viruses in model systems (Jin 2003).

An alternative approach to RSV vaccine development is the use of bovine RSV. A chimeric bovine RSV with either the human F protein alone or both the human F and 20 G protein was evaluated for its efficacy in chimpanzees. This vaccine candidate was restricted in replication to such a degree that animals were not protected after wild type h-RSV challenge (Buchholtz 2000).

Thus, currently there is no effective h-RSV vaccine available in the art. All RSV vaccine candidates that have been tested in animal models are unusable in humans. 25 There is thus a long felt need in the art for RSV vaccines that are both effective and safe and it is an object of the present invention to provide for such vaccines.

Description of the invention

Definitions

30 In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one

of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".

The term "virion" as used herein refers to a virus particle that contains the nucleocapsid protein, the viral genome and the replicase complex in a lipid envelop that
5 contains the viral structural glycoproteins.

The terms "infectivity of a virus", "infectious virus", "infectious virus particle" or "infectious virion" denote viruses, virus particles or virions that are capable of entering suitable host cells and initiating a virus replication cycle, whether or not this leads to the production new virus that is infectious.

10

Detailed description of the invention

In a first aspect the present invention relates to a virion of a pneumovirus. The virion comprises a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus
15 produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion.

The pneumovirus preferably is a Respiratory Syncytial Virus (RSV), more preferably a human or bovine RSV. The human RSV may either be a subgroup A or B
20 virus, and preferably is a clinical isolate, more preferably an isolate that has not been extensively passaged *in vitro* (preferably passaged less than 10, 8, 6 or 5 times as described in the Examples). Therefore, any RSV strain or isolate may be used in the context of the present invention, whereby is understood that the invention is only exemplified by means of the particular human RSV isolate 98-25147-X, referred to as
25 RSV isolate X. Further preferred is that virus is a recent clinical isolate whereby recent is defined as being first isolated less than 10, 8, 6, 4, 3, or 2 years ago. It will be understood that although the nucleotide sequences in the virion do not need to correspond to those of the recent isolate, preferably, the amino acid sequences of the proteins present in the virion of the invention are identical to the proteins as they occur
30 in a recent clinical isolate.

The viral genome comprises at least one mutation in at least one viral gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the infectivity of the virus is as defined above. Thus, the protein that is essential for

infectivity of the pneumovirus is a protein that is essential for the capability of the virion of the invention to enter a suitable host cell and initiate a viral replication cycle, whereby the replication cycle does not necessarily lead to the production of new infectious virions. In preferred virions of the invention the mutation causes the virion to 5 lack infectivity *in vivo*, i.e. in a suitable host organism, whereby the virions may still be infectious for suitable host cells cultured *in vitro*.

In a preferred virion of the invention, the mutated gene that codes for a protein essential for infectivity of the pneumovirus, is a gene, which codes for a structural protein of the virus. A structural protein of a pneumovirus is herein understood to be a 10 protein that is present in virions of wild-type infectious virus. Preferred genes coding for structural proteins to be mutated in the virions of the invention are the genes coding for the attachment protein G and/or the fusion protein F, whereby the G protein is most preferred. Deletion and/or functional inactivation the gene coding for G protein serves several purposes and prevents a number of problems and complications of current RSV 15 vaccine candidates. One purpose is vaccine safety: RSV without G protein is highly attenuated in its host (Karron 1997, Schmidt 2002) because it will not be able to efficiently infect host cells. One complication is that the G protein is strongly implicated in causing undesired immunological responses, including enhanced immune pathology (Alwan 1993, Srikiatkachorn 1997b) and possible skewing of the immune 20 system towards an allergy (and asthma-) prone state under certain genetic predispositions (Openshaw 2003, Peebles 2003). This will be prevented by deletion or inactivation of the G gene. A pneumoviral virion of the invention comprising a viral genome that has an inactivating mutation in the gene coding for a G attachment protein, and comprising the G attachment protein in a form and in an amount that is required for 25 infectivity of the virion is referred to as a " $\Delta G+G$ " (pneumo)virus or virion. Similarly, the virion that has the inactivating mutation in the gene coding for a G attachment protein, but which is not complemented *in trans* with a functional amount of G protein is referred to as a " ΔG " (pneumo)virus or virion.

The pneumoviral virions of the invention are thus transiently and functionally 30 reconstituted with an externally encoded protein that is essential for infection. Preferably the externally encoded protein that is essential for infection is the attachment protein G and/or the fusion protein F, whereby the G protein is most preferred. Preferably the externally encoded protein that is essential for infection is of the same

viral subgroup (A or B) as the genome that is present in the virion. More preferably the externally encoded protein that is essential for infection is homologous to the genome that is present in the virion, whereby is meant that the protein has the same amino acid sequence as the amino acid sequence that was encoded in the genome of the virus prior 5 to its inactivation. Alternatively, this may mean that the externally encoded protein has the same amino acid sequence as present in a wild type virion of which the amino acid sequences with one or more internally encoded proteins have 100% identity with their counter part in the virion of the invention.

In the virions of the invention, the mutation in the gene of the essential structural 10 protein is a mutation that causes the virus produced from only the viral genome to lack the protein or to express a biologically inactivated protein. Production of virus from only the viral genome is understood to mean virus produced exclusively from the viral genome as present in the virions and in the absence of any coding sequence complementing the viral genome *in trans*. The viral genome as present in the virions is 15 thus incapable of directing expression of the essential structural protein. This may be achieved in various ways known to the skilled person, including e.g. inactivation of the translation initiation codon, introduction of stop codons near the N-terminus of the encoded protein, one or more frame-shift mutations, deletion of one or more fragments from the gene. Preferably the gene is inactivated by deletion of at least 10, 20, 50, 75, 20 90 or 95% of the sequence coding for the essential structural protein. Most preferred is however, a virion in which the mutation comprises deletion of the (entire) sequence coding for the protein.

Explicitly included in the invention are virions in which more than one mutation 25 is present. In particular, more than one viral protein-coding gene may comprise mutations that inactivate or alter the function of the protein in question, or which cause the protein to lack from the virions as described above. E.g. the cold-passaged or heat-sensitive mutations as known in the art may be combined with inactivation of the essential structural proteins as disclosed in the invention above.

Clearing of pneumoviruses like RSV from the infected host organisms requires 30 proper cellular immunity, which will not be effectively mounted without infection of epithelial cells by the virus. However, the mutant pneumoviruses of the invention lack genetic information for a protein that is essential for infection of host cells *in vivo*. Therefore the present invention discloses methods for the production of the mutant

pneumoviruses, which include replication of mutant pneumoviruses in cells that complement (*in trans*) for the absence of the protein that is essential for infection.

In another aspect the invention thus pertains to a method for producing the above defined mutant pneumoviral virions. The method is a method for producing 5 pneumoviral virions, whereby the virions comprise a viral genome that has a mutation in a gene coding for a protein that is essential for (*in vivo*) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The method comprises the 10 steps of: (a) infecting a culture of a first host cell with a pneumovirus comprising a viral genome that has a mutation as defined above, whereby the host cell comprises an expression vector which directs expression, either transiently or constitutively, in the host cell of the protein in a form and in an amount that is required for infectivity of the virion; and, (b) recovery of the virions from the infected host cell culture. Recovery of 15 virions from the infected host cell culture may include either or both recovery from the culture medium as well as recovery from the cells.

The first host cell may be any host cell in which the pneumovirus is capable of replication, with or without the simultaneous expression *in trans* of the protein that is required for infectivity of the virion. Suitable host cells for this purpose are e.g. African 20 green monkey kidney cell cultures (such as e.g. Vero, ECACC lot 10-87, 134th passage, 1990, EMEA approved).

In a preferred method of the invention, the pneumovirus that is used to infect the culture of a first host cell culture, is produced in a method comprising the steps of: (a) providing to a second host cell one or more expression vectors which direct expression 25 in the host cell of: (i) a viral genomic RNA that has a mutation in a gene coding for a protein that is essential for (*in vivo*) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity; and, (ii) a pneumoviral polymerase enzyme complex and optionally one or more further viral proteins; and, (b) culturing the second host cell whereby the virions are produced. 30 In a preferred method, the virions produced by the second host cell are amplified by one or more further cellular infection steps employing host cells which are the same or different from the second host cell.

The second host cell may be any host cell in which the pneumovirus is capable of replication, with or without the simultaneous expression *in trans* of the protein that is required for infectivity of the virion. Suitable host cells for this purpose are e.g. African green monkey kidney cell cultures (such as e.g. Vero, ECACC lot 10-87, 134th passage, 5 1990, EMEA approved), or Hep-2 cells. The second host cell may be the same as or different from the first host cell.

In the methods of the invention, the viral genomic RNA is transcribed from a viral DNA copy that is under the control of a bacteriophage DNA-dependent RNA polymerase promoter and whereby the (second) host cell is provided with an expression 10 vector which directs expression in the host cell of the bacteriophage DNA-dependent RNA polymerase. Preferably, the bacteriophage DNA-dependent RNA polymerase is a T7, T3 or SP6 polymerase.

The pneumoviral polymerase enzyme complex that is expressed from one or more expression vector(s) in the second host cell at least includes the L, P, N proteins 15 expressed from their corresponding genes or cDNA's in the expression vector(s). For improved efficiency of viral assembly and packaging of the naked viral genomic RNA, optionally, one or more further viral proteins are expressed in the second host cells. Preferred viral proteins for this purpose include the viral matrix membrane proteins of which the M2-1 protein is particularly preferred. The L, P, N, M2-1, G or F proteins are 20 preferably derived from the viral genome of the viral isolate which is introduced and expressed in the host cell, but alternatively also homologous proteins from other heterologous viral or non viral sources may be used.

The skilled person will appreciate that a wide variety of expression vectors and regulatory sequences (such as promoters) are available in the art for expression of the 25 viral genomic RNA, the DNA-dependent RNA polymerase, pneumoviral polymerase enzyme complex and optional further viral proteins, as well as the essential structural protein, in the first and/or second host cells (see e.g. Sambrook and Russell (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York).

30 For reverse genetics of RNA viruses, i.e. expression of a recombinant RNA virus such as the virions of the present invention, a cDNA copy of the viral genomic RNA is cloned into plasmids and is placed under the control of sequences that will allow synthesis of RNA from the DNA under certain conditions. Generally, the promoter

sequence for bacteriophage RNA polymerase (e.g. the T7 RNA polymerase) is placed upstream of the DNA copy of the RNA genome, while an appropriate terminator for the RNA polymerase is placed downstream of the genome. Self-cleaving ribozyme sequences are placed upstream of the terminator sequences, to allow synthesis of RNA with the correct terminal nucleotides. Correct terminal sequences are generally required to rescue virus from the synthetic RNA. For non-segmented negative strand RNA viruses, co-expression of the polymerase enzyme complex (N, P and L proteins for Paramyxoviruses) along with the genomic or anti-genomic RNA is required to obtain recombinant virus (reviewed by Neumann 2002 and exemplified in the Examples herein).

Other preferred methods may comprise the further step of isolating and/or purifying the virions of the invention and/or formulating these virions into pharmaceutical compositions. Methods for isolating and/or purifying virions are well known to the skilled virologist. Such methods e.g. include various centrifugation techniques (e.g. differential or density centrifugation), or chromatographic techniques. A method for formulating the virions of the invention into a pharmaceutical composition at least comprises the step of mixing the virions with a pharmaceutically acceptable carrier as defined below.

In a further aspect the invention relates to a composition comprising a virion as defined above or obtainable in a method as defined above, and a pharmaceutically acceptable carrier. The composition preferably is a pharmaceutical composition that is preferably suitable for use as a vaccine, i.e. the composition preferably is a vaccine.

In a yet another aspect the invention provides for a pharmaceutical preparation comprising as active ingredient a virion according to the invention, and a pharmaceutically acceptable carrier. Pharmaceutically acceptable stabilising agents, osmotic agents, buffering agents, dispersing agents, and the like may also be incorporated into the pharmaceutical compositions. The preferred form depends on the intended mode of administration and therapeutic application. The pharmaceutical carrier can be any compatible, non-toxic substance suitable to deliver the reconstituted viral membranes to the patient. Pharmaceutically acceptable carriers for intranasal delivery are exemplified by water, buffered saline solutions, glycerin, polysorbate 20, cremophor EL, and an aqueous mixture of caprylic/capric glyceride, and may be buffered to provide a neutral pH environment.

For administration by inhalation, the pharmaceutical compositions of the present invention are conveniently delivered in the form of an aerosol spray from pressurised packs or a nebuliser, wherein the virions are present in a carrier as described for intranasal delivery but with the use of a suitable propellant, e.g.,

5 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

Methods for preparing intranasal or inhalant compositions are well known in the art and described in more detail in various sources, including, for example,

10 Remington's Pharmaceutical Science (15th ed., Mack Publishing, Easton, PA, 1980) (incorporated by reference in its entirety for all purposes). The virions may thus be formulated as the active component in any preparation for vaccination, which may further e.g. include carriers, adjuvants, stabilisers, solubilisers, preservatives and other excipients known in the art, to allow or to aid efficient administration of the preparation
15 for vaccination to individuals, preferably human and live stock or farm animals (such as cows, pigs, horses, goats, sheep).

In a further aspect, the invention relates to a method for vaccination against, or for prophylaxis or therapy (prevention or treatment) of an pneumoviral infection by administration of a therapeutically or prophylactically effective amount of (a
20 pharmaceutical composition comprising) the virions of the invention as defined above, or obtainable as defined above, to a subject in need of prophylaxis or therapy.

Preferably, the virions are administered intranasally.

The invention similarly relates to virions of the invention as defined above, or obtainable as defined above, for use as a medicament, preferably a medicament for
25 vaccination against, or for prophylaxis or therapy of a pneumoviral infection. The invention further relates to the use of the virions of the invention in the manufacture of a medicament for vaccination against, or for prophylaxis or therapy of a pneumoviral disease or infection. Preferably the medicament is a preparation for intranasal administration.

30 The compositions comprising the virions of the invention for vaccination are preferably administered intranasally to appropriate hosts. In one embodiment, calves are to be protected from b-RSV infections. In yet another embodiment, humans, of which preferably infants and elderly or immune compromised individuals are protected

from h-RSV infections. Formulations preferably comprise formulations suitable for administration as intranasal drops or spray, preferably a nasal spray. The $\Delta G+G$ -pneumoviral particles in the composition will infect epithelial cells of the upper respiratory tract only once because the second generation virions produced from the initially infected URT epithelial cells lack the G attachment protein for which the coding sequence has been removed from the genome. These ΔG -virions are therefore non-infectious *in vivo* in host organisms. However, the initial single cycle of infection allows for the development of appropriate cellular immunity - that is a response capable of clearing wild-type virus infection - to be mounted against pneumovirus, or RSV in particular, while protective antibodies against F - i.e. antibodies that will prevent lower respiratory tract infection - will be elicited by the vaccine and the non-infectious progeny. Anti-F antibodies are effective in limiting RSV infection, as is shown by the effectiveness of Palivimuzab treatment, which is a humanised monoclonal antibody against F. This is the basis of the efficacy of the recombinant live attenuated pneumoviral vaccines of the invention. These live viral vaccines solves a number of problems associated with current pneumovirus vaccine candidates. The presence of the G-protein in its natural context in the virion allows for the development of appropriate cellular immunity whereas the undesirable effects of immunity against the isolated G protein that is largely responsible for immune enhancement of b-RSV and h-RSV pathology in cattle and humans respectively, is avoided.

Description of the figures

Figure 1: Diagram of construction of pRSVX ΔG . Upper line represents RSV isolate X genomic RNA, with genes indicated. Boxes below represent RT-PCR products and oligonucleotide duplexes used for construction. Numbers inside boxes indicate the oligonucleotide numbers as listed in table I. Restriction sites introduced for cloning are indicated. The final cloning scheme is indicated below: circles are plasmids and the arrows show the order of cloning.

Figure 2. Alignments showing the differences between RSV isolate X and pRSVX ΔG sequences. Sequences are shown as alignment of genomic sense. For pRSVX ΔG only nucleotides differing from RSV isolate X are indicated. Similar sequences are indicated by dots (.) and gaps are indicated by (-). Gene start signals are single underlined, gene stop signals double underlined, and the genes are indicated in the captions. Boxes

outline the restriction enzyme recognition sites resulting from the nucleotide changes introduced.

Figure 3. Identification of sequence markers in RSV RT-PCR amplification products, digestions digests: a) MluI, b) XmaI, c) SexA-I, d) SnaB-I.

5 Figure 4. Growth curves of RSV isolate X and ΔG-RSV isolate X. Vero (solid lines) and Hep-2 (dashed lines) cells were infected with virus at MOI=0.1 and incubated at 37°C. At the indicated time points cells were harvested and CCID50 titres were determined on Vero cells.

Table I. Primers used for RT-PCR cloning of RSV isolate X.

10 Table II. Primers used for cloning of helper plasmids and for plasmids used for construction of stable cell lines.

Table III. Primers used for diagnostic RT-PCR on RNA from RSV infected Vero cells.

Table IV. Results cotton rat immunization experiments, protection against RSV infection and RSV-induced pathology by ΔG-RSV isolate X immunization.

15

Examples

The current invention is illustrated by the following non limiting examples that are merely used to illustrate specific embodiments of the invention and should not be read as limiting the general scope or any aspect of the invention.

20

Example 1

Viral isolate, virus isolation, propagation and storage

The basis for the recombinant h-RSV clone is a clinical RSV isolate, obtained from the Leiden University Medical Centre diagnostic laboratory. This virus, named 25 98-25147-X, coded after the patient from which it was isolated, was derived from a diagnostic test on Hep-2 cells in the period 21-24 December 1998. It was later determined to be a subtype A isolate and is designated RSV isolate X. The virus was passaged 4 times on Hep-2 cells in T75 bottles in DMEM (Gibco), 10% FCS, pen/strep/glu and subsequently five times on Vero cells in T75 bottles on in DMEM 30 (Gibco), 10% FCS, pen/strep/glu. The resulting RSV isolate X virus was used as working stock and stored at -135°C in 25% or 45% sucrose.

Example 2

Construction of RSV-X cDNA encoding viral genome

Total RNA was obtained by phenol-guanidine isothiocyanate extraction (Trizol, Invitrogen) of stock RSV isolate X infected Vero cells. cDNA was prepared by reverse transcription using Thermoscript (Invitrogen) reverse transcriptase using random hexamer primers. This cDNA was used as template for PCR using High fidelity Taq polymerase (Invitrogen) using specific primers containing restriction enzyme recognition sites (Table I and sequence listing). Primers were designed based on the published sequences of RSV-A2 (Genbank accession no M74568) and RSV-RSS2 (Genbank accession no U39662).

5 PCR products were first cloned individually in different vectors: primer pairs, vectors, restriction enzyme recognition sites and resulting vector name are listed below.

RSV021/RSV047: pCAP vector (Roche), bluntly into Mlu N1, pCAP3 (SH/M/P region)

10 RSV018/019: pCAP vector, bluntly into Mlu N1, pCAP2 (G region)

15 RSV016/RSV017: PUC21, Mlu I /Bam HI, pUK5 (M2-2/M2-1/F region)

RSV024/RSV025a : PUC21, Bam HI/Afl II, pUK1 (NS2/NS1 region)

RSV022/ RSV023: PUC21, EcoR V, pUK4 (N region)

RSV014/ RSV015: PUC21, Kpn I/Mlu I, pUK2 (L region)

10 At least two individual clones derived from two independent cDNA templates were sequenced; regions containing differences between the two clones were sequenced on a third clone. If necessary, clones were repaired using standard molecular biology techniques known by the skilled person. Additional PCR products covering the binding sites of the primers used for cloning were obtained and sequenced. The 5' genomic termini were determined by poly-adenylation of genomic RNA, followed by

20 RT-PCR with an oligo(d)T containing primer ALG018:

TTAAAAGCTTTTTTTTTTTTTTTTT

25 and an NS1 gene primer RSV126:

AATTCTGCAGGCCATCTCTAACCAAAGGAGT.

This fragment was cloned into pUC21 using Hind III/Pst I. The 3'-end was determined

30 by RACE (rapid amplification of cDNA ends) ligation PCR. All sequences were assembled to yield the RSV-X consensus sequence (Seq ID No. 1).

All sequences were confirmed by PCR cycle sequencing using the BigDye terminator kit (Applied Biosystems) and analysed by an ABI Prism 310 genetic analyser.

5

Example 3Construction of ΔG-RSV isolate X full length plasmid

The full-length cDNA spanning the entire RSV isolate X genome was assembled by sequential ligation of PCR fragments (Figure 1). The “trailer” end is preceded by the promoter for the bacteriophage T7 polymerase. To generate correct 3’ ends the cDNA 10 “leader” end is fused to the hepatitis delta virus ribozyme (HDVR), followed by a terminator of the T7 RNA polymerase transcription (see Figure 1).

First, two sets of complementary oligomers encoding the HDVR and the T7 terminator RSV026/RSV027 oligo’s and RSV028/029 oligo’s were phosphorylated with T4 DNA kinase, hybridised and ligated into clone pUK1 (containing genes 15 NS1/NS2) via Rsr II /Not I, giving plasmid pUK3. Then, the Xma I/SexA I fragment of clone pUK4 containing N was ligated into plasmid pUK3 via Xma I/SexA I. This plasmid (pUK6) contains the region from the N gene up to the 3’ leader sequence, fused to the HDVR and a T7 terminator.

Secondly, the Xma I/Eco RV fragment of plasmid pCAP3 was inserted in 20 plasmid pUK5 using Xma I and a filled-in Hind III site. This yields plasmid pUK8. Subsequently, pUK 8 was digested with BssH II and BsiW I, ends were filled-in with Klenow polymerase and religated. This plasmid contains the genes M2-2, M2-1, F, SH, M and P and is named pUK9.

To synthesise a low-copy number vector for the RSV isolate X cDNA, two 25 complementary oligomers, RSV011: AGCTTGGCCCGTCGACCCGGACCGTCAATGGGTACCAT and RSV012: CGATGGTACCCGATCGACCGTCCGGTCGACGCCGCA were phosphorylated with T4 DNA kinase, hybridised and inserted in the alkaline phosphatase treated and Cla I /Hind III digested plasmid pACYC184 (New England 30 Biolabs). The resulting plasmid is named pACYC184-MCS. Subsequently a Mlu I-Knp I fragment of pUK2 containing the T7 promoter and L gene was inserted, this intermediate plasmid is named pACYC1. Then, the region from the N gene up to the 3’-leader sequence, including the fused HDVR and T7 terminator sequence of pUK6

was added to pACYC1 using Xma I/Not I. This gives intermediate plasmid pACYC2. Finally, the Xma I /Mlu I fragment of pUK9 containing the M2-2, M2-1, F, SH, M and P genes was inserted into pACYC2, yielding plasmid pACYC3, comprising the whole RSV genome of strain X lacking the G gene. Sequence analysis of the latter plasmid 5 revealed a deletion in the HDVR region, which was repaired and the resulting plasmid is named pRSVX Δ G.

In addition to construct pRSVX Δ G, construct pACYC24 was generated in which the genomic RSV isolate X insert is reverse complemented via inverse PCR. From the construct, antigenomic RSV RNA can be synthesised. In pACYC24, the T7 promoter 10 precedes the 3'-leader sequence, whereas the HDVR and T7 terminator are fused to the 5'-trailer sequence.

All restriction enzyme recognition sites used to construct pRSVX Δ G are located inside the RSV intergenic regions and do not alter coding sequences or affect transcription signals (as shown in Figure 2).

15

Example 4

Construction of helper plasmids

Helper plasmids expressing several RSV proteins were constructed as follows.
20 All required genes are derived from lab-strain RSV-A2 (ATCC #VR1302). Virus was plaque-purified on Hep-2 cells and subsequently used to infect Vero cells. Total RNA was isolated from these cells by phenol-guanidine isothiocyanate extraction (Trizol, Invitrogen) and subjected to RT-PCR using High Fidelity Taq polymerase (Invitrogen) and a set of primers specific for RSV genes L, P, N and M2-1 respectively (see Table II). PCR products were subsequently cloned into expression plasmids pcDNA3,
25 pcDNA6 or pCI, using restriction enzyme recognition sites as indicated in the table II. Clone sequences were confirmed by PCR cycle sequencing using the BigDye terminator kit (Applied Biosystems) and analysed by an ABI Prism 310 genetic analyser.

30

Example 5

Construction of G-producing Vero cell-lines

Cell lines producing RSV-G protein were constructed using several methods:

In method 1, the G gene from either RSV-A2 or RSV isolate X, or the G gene from RSV-A2, in which the internal translation initiation codon had been disabled by modification using primers RSV033 and RSV 034, were cloned into expression vector pcDNA3 or pcDNA6 (Invitrogen) using RT-PCR on RNA from RSV-A2 or RSV isolate X infected Vero cells using primers as indicated in Table II. The plasmids were introduced into Vero cells using either chemical agents CaCl₂, co-precipitation, liposome-based or electroporation (Ausubel 1989). Two methods for isolating stable cell lines were used. In the first method, 72 hours after transfection, cells were split using various dilutions into fresh medium containing selective medium, zeocin for 5 pcDNA3 and blasticidin for pcDNA6. Cells were fed with selective medium every 3-4 days until cell foci were identified. Single colonies were picked and transferred in to 96-well plate, or seeded in various dilutions to obtain single cells in a 96 well plate. Antibiotic resistant colonies were tested on expression of RSV-G by immunostaining techniques or FACS using RSV G-specific antibodies. Colonies expressing G were 10 passaged, and were designated as stable cell lines expressing G. The second method comprises FACS sorting using RSV-G specific antibodies 72 hours after transfection. RSV-G expressing cells were seeded in a serial dilution to obtain single cells in a 96-well plate and cultured with selective medium. Single cell colonies were passaged on 15 selective medium and subsequently tested again for expression of RSV-G, resulting in 20 cell lines expressing RSV-G.

In method 2, the Flp-In system (Invitrogen) is used to produce Vero cells with target gene insertion sites at chromosomal positions which allow different levels of target gene expression. The RSV-G gene, derived from the plasmids from method 1 but with a modification (introduced using primer RSV151: Table II) of the G translation 25 initiation codon surrounding sequence to allow higher translation levels, were inserted in each of these cell lines using the system-generic method, resulting in Vero cell lines stably expressing different levels of G protein.

In method 3, Vero cells were transiently made to express the G protein, by either 30 transfection with the expression plasmids containing the G gene from method 1, or by infection with Modified vaccinia virus Ankara (MVA) (Sutter 1992) or fowlpox viruses (Spehner 1990) expressing the G protein.

Example 6

Construction of bacteriophage T7-polymerase-producing cell lines

The bacteriophage T7 polymerase gene is PCR amplified from plasmid pPRT7 (van Gennip 1997), containing the gene, using primers ALG022 and ALG023 (Table II). The PCR product is cloned into pcDNA6b vector, using Hind III/Xba I, yielding 5 plasmid pc6T7pol. Vero cells were transfected using lipofectamine 2000 as recommended by the manufacturer (Invitrogen). 72 hours after transfection cells were split and grown in fresh medium containing blasticidin. Cells were fed fresh medium every 3-4 days and split twice to obtain larger culture volumes. 20 days after transfection, blasticidin resistant cells were transfected with reporter plasmid pT7- 10 IRES2-EGFP using lipofectamine 2000. For the construction of plasmid pT7-IRES2-EGFP, first plasmid pT7-EGFP was constructed by inserting via HindIII/BamH1 in plasmid p-EGFP-N1 (Clonetech) a set of complementary oligomers encoding for the T7 promoter sequence (ALG32: AGCTAATACGACTCACTATAAGGGAGACGCGT and ALG33: GATCACGCGTCTCCCTATAGTGAGTCGTATT). Plasmid pT7- 15 IRES2-EGFP was then constructed by cloning the T7-EGFP fragment of plasmid pT7-EGFP into plasmid p-IRES2-EGFP via Xma1-Not1. Cells expressing EGFP were sorted by FACS and grown in limited dilution to obtain single cell colonies. Single colonies expressing T7 RNA polymerase were tested for stability, grown to larger culture volumes and stored.

20

Example 7Method to produce recombinant ΔG-RSV isolate X virus

Hep-2 cells were cultivated in DMEM + 10% FCS (foetal calf serum) + penicillin/ streptomycin/ glutamine, whereas Vero cells and derivatives thereof are 25 cultivated in M199 + 5% FCS + pen/strep/glu. Cells were grown overnight to 80% confluence in 10 mm² dishes at 37°C. For Vero and Hep-2 cells, cells were infected with modified virus Ankara-T7 (MVA-T7)(Sutter 1992, Wyatt 1995) or fowlpox-T7 virus (Britton 1996) at MOI = 3 (multiplicity of infection 3) and incubated at 32°C for 60 min prior to transfection, to allow expression of bacteriophage T7 polymerase. The 30 cells (Hep-2, Vero or Vero-T7 cells) were washed with Optimem medium (Optimem 1 with glutamax, Invitrogen) and subsequently transfected with helper plasmids encoding the N, P, L and M2.1 genes of RSV and with plasmid pRSVXΔG, using Lipofectamine2000 (Invitrogen) in Optimem (total volume 500 µl). The following

amounts of plasmids were added: 1.6 μ g pRSVX Δ G, 1.6 μ g pcDNA6-A2-N, 1.2 μ g pcDNA3-P, 0.4 μ g pcDNA6-A2-L, 0.8 μ g pcDNA6-A2-M2.1. After 3-4 hrs of incubation at 32 $^{\circ}$ C, 500 μ l of Optimem medium with 2% FCS was added and the cells were incubated at 32 $^{\circ}$ C for 3 days. Cells were then scraped and the mixture of scraped 5 cells and medium containing the rescued virus was used to infect fresh cultures of Vero or Hep-2 cells grown in DMEM + 2% FCS + pen/strep/glu. The latter procedure was repeated for 4-5 times to obtain high titre virus stocks.

Identity of Δ G-RSV isolate X virus was confirmed by RT-PCR on RNA isolated from Δ G-RSV isolate X infected Vero cells and digestion of the obtained products with 10 the unique restriction enzymes whose recognition sites were introduced into pRSVX Δ G (figure 2). RSV isolate X was used as control.

For the identification of sequence markers in RSV, Vero cells were infected with RSV isolate X or with Δ G-RSV isolate X with an MOI= 0.1. 72 hrs after infection, RNA from culture supernatants was isolated and used as template for RT-PCR. 15 Primers were designed to flank the inserted sequence markers in the recombinant Δ G-RSV isolate X virus. After RT-PCR, the obtained products were digested with the appropriate restriction enzymes. The following digestion products were obtained (figure 3):

- a) PCR with primer RSV065 (GTCCATTGTTGGATTTAATC) and RSV093 20 (CAAGATAAGAGTGTACAATACTGTC) and digestion with Mlu-I yielded the expected fragments of 937 bp for RSV isolate X, and 459 and 478 bp for Δ G-RSV isolate X
- b) PCR with primers RSV105 (GTTGGATTGAGAGACACTT) and RSV113 (AGTATTAGGCAATGCTGC) followed by digestion with Xma-I yielded the 25 expected fragments of 880 bp for RSV isolate X, and 656 and 224 bp for Δ G-RSV isolate X
- c) PCR with primers RSV112 (CCCAGTGAATTATGATTAG) and RSV160 (AATTGGATCCATGGACACAAACCCACAATGA) and digestion with SexA-I yielded the expected fragments of 694 bp for RSV isolate X, and 492 and 202 bp for 30 Δ G-RSV isolate X
- d) PCR with primers RSV098 (TGGTAGTTCTCTGGCTCG) and RSV114 (ATCCCCAAGTCATTGTTCA) followed by digestion with SnaB-I yielded the

expected fragments of 1820 bp for RSV isolate X, and 507 and 387 bp for ΔG-RSV isolate X.

Growth characteristics of ΔG-RSV isolate X compared to RSV isolate X were determined on Vero and on Hep-2 cells (figure 4).

5

Table III. Primers used for diagnostic RT-PCR on RNA from RSV infected Vero cells.

<i>Primer name</i>	<i>Sequence</i>
RSV065	GTCCATTGTTGGATTAATC
RSV093	CAAGATAAGAGTGTACAATACTGTC
RSV098	TGGTAGTTCTCTCTGGCTCG
RSV105	GTTGGATTGAGAGACACTT
RSV112	CCCAGTGAATTATGATTAG
RSV113	AGTATTAGGCAATGCTGC
RSV114	ATCCCCAAGTCATTGTTCA
RSV160	AATTGGATCCATGGACACAACCCACAATGA

Example 8

Method to produce recombinant ΔG+G-RSV isolate X virus

ΔG-RSV isolate X virus, derived from transfected Vero cells, was passaged several times to obtain titres of at least 10^5 pfu/ml (plaque forming units per ml). Different moi's of this virus were then used to infect the Vero cell line producing RSV-G protein. The resulting ΔG+G-RSV isolate X was harvested from the medium and/or 15 from the cells and analysed for the presence of the G protein in the virions by immunodetection techniques. Infectivity titres were determined on Vero or Hep-2 cells, and the integrity of the ΔG-genome was determined using RT-PCR on viral RNA extracted from cells infected with ΔG+G-RSV isolate X virus. Virus was stored at –135° C in 25% or 40% sucrose.

20

Example 9

Method to protect in a cotton rat animal model against RSV infection and RSV-induced pathology by ΔG-RSV isolate X immunization

Protection experiments were performed in cotton rats (*Sigmodon hispidus*, 5-6 weeks old, 4-6 animals per group and both sexes). In initial experiments, this animal was shown to be sensitive to RSV infection and to exhibit severe vaccine-mediated lung pathology as described by Prince, 2001 and which closely mimics the human situation.

After intranasal application of RSV lung pathology was characterized by inflammation infiltrate in and around bronchus/bronchioli and hyperplasia of epithelium. A more severe pathology was seen upon intramuscular immunization with formalin-inactivated RSV-A2 followed by an intranasal challenge with RSV-A2. In addition to the above-mentioned pathology, perivascular and peribronchiolar infiltrate and alveolitis were observed, characteristic for an immune-mediated pathology. These observations were used as "internal" reference for all immunization and challenge experiments.

Infection and immunization of cotton rats with RSV preparations was done intranasally, in both nostrils. Cotton rat lungs were examined for pathology lightmicroscopically and virus titres at different time points post-challenge or post-infection/immunization were determined on Vero cells using serial dilutions of lung homogenates with RSV specific ELISA to yield CCID₅₀ titres and immunostaining using RSV specific abs to yield pfu titres. After immunization twice with ΔG-RSV isolate X cotton rats were fully protected against infection and pathology caused by RSV isolate X in the lungs. The results from several experiments are summarized in Table IV.

Table IV:

<i>infection with:</i>		<i>t¹</i>	<i>V²</i>	<i>lung pathology day 5</i>		<i>lung t³</i>
		<i>post infection</i>				
ΔG-RSV		5	100	yes, moderate		below detection
isolate X						
RSV-A2		5	100	yes, strong		2*5
RSV isolate X		5	100	yes, strong		4*5
<i>immunization</i>	<i>t¹</i>	<i>V²</i>	<i>challenge day</i>	<i>t¹</i>	<i>V²</i>	<i>lung pathology day 5</i>
<i>day 0 and 21</i>		42		<i>post challenge</i>		
2x ΔG-RSV	5	100	RSV isolate X	5	100	no
						below

isolate X						detection	
	mock	100	RSV isolate X	5	100	yes, strong	5

¹: virus titres in logs pfu/ml²: volume in μ l per animal, which is half this volume in each nostril³: virus titres in logs per gram lung, detection limit is 10^2 CCID₅₀

5

References

- Alwan WH, Record FM, Openshaw PJ. Phenotypic and functional characterisation of T cell lines specific for individual respiratory syncytial virus proteins. *J Immunol.* 1993, 150(12):5211-8.
- 10 F.M. Ausubel, R. Brent, R. E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl, *Current Protocols in Molecular Biology*, John Wiley and Sons, New York, 1997
- Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. *J Gen Virol.* 2000, 81(Pt 10):2519-23.
- 15 Britton P, Green P, Kottier S, Mawditt KL, Penzes Z, Cavanagh D, Skinner MA. Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. *J Gen Virol.* 1996, 77 (Pt 5):963-7.
- 20 Buchholz UJ, Granzow H, Schuldt K, Whitehead SS, Murphy BR, Collins PL. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. *J Virol.* 2000, 74(3):1187-99.
- 25 Cane PA, Matthews DA, Pringle CR. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. *J Gen Virol.* 1991, 72 (Pt 9):2091-6.
- Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. *Vaccine.* 1990, 8(2):164-8
- 30 Crowe JE Jr. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. *Vaccine.* 1998, 16(14-15):1423-32. Review.

- Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. *Vaccine*. 2000, 18(17):1763-72.
- 5 Greenough A, Thomas M. Respiratory syncytial virus prevention: past and present strategies. *Expert Opin Pharmacother*. 2000, 1(6):1195-201.
- Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. *Vaccine*. 2003, 10 21(25-26):3647-52.
- Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterisation of a cold-passaged, attenuated RSV subgroup B mutant. *Proc Natl Acad Sci U S A*. 1997, 94(25):13961-6.
- 15 Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. *Am J Epidemiol*. 1969, 89(4):422-34.
- Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M. Protection against respiratory syncytial virus infection by DNA immunization. *J Exp Med*. 1998, 188(4):681-8.
- 20 Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. *Clin Ther*. 2000, 22(11):1357-69.
- Mufson MA, Belshe RB, Orvell C, Norrby E. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. *J Infect Dis*. 1988, 157(1):143-8.
- 25 Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? *J Gen Virol*. 2002, 83(Pt 11):2635-62. Review.
- 30 Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. *Pediatr Infect Dis J*. 2003, 22(2 Suppl):S58-64; discussion S64-5. Review.

- Peebles RS Jr, Hashimoto K, Graham BS. The complex relationship between respiratory syncytial virus and allergy in lung disease. *Viral Immunol.* 2003;16(1):25-34. Review.
- Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaia N, Nguyen TN,
5 Power UF. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. *Vaccine.* 2003, 21(19-20):2651-60.
- Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen TN, Binz H. Induction of protective immunity in rodents by vaccination with
10 a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. *Virology.* 1997, 230(2):155-66.
- Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. *J Gen Virol.* 2001, 82:2881-8.
- 15 Robinson RF, Nahata MC. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. *Am J Health Syst Pharm.* 2000, 57(3):259-64. Review. Erratum in: *Am J Health Syst Pharm* 2000 Apr 1;57(7):699.
- Sambrook J., Fritsch EF, Maniatis T. *Molecular Cloning. A Laboratory Manual*,
2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989
- 20 Schmidt U, Beyer J, Polster U, Gershwin LJ, Buchholz UJ. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. *J Virol.* 2002, 76(23):12355-9.
- Siegrist CA, Plotnicky-Gilquin H, Cordova M, Berney M, Bonnefoy JY, Nguyen
25 TN, Lambert PH, Power UF. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. *J Infect Dis.* 1999, 179(6):1326-33.
- Spehner D, Drillien R, Lecocq JP. Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus
30 fusion gene. *J Virol.* 1990, 64(2):527-33.
- Srikiatkachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia

during experimental murine respiratory syncytial virus infection. *J Exp Med.* 1997a, 186(3):421-32.

Srikiatkachorn A, Braciale TJ. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. *J Virol.* 1997b, 71(1):678-85.

5 Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc Natl Acad Sci U S A.* 1992, 89(22):10847-51.

Van Gennip HG, van Rijn PA, Widjojoatmodjo MN, Moormann RJ. Recovery of infectious classical swine fever virus (CSFV) from full-length genomic cDNA clones by a swine kidney cell line expressing bacteriophage T7 RNA polymerase. *J Virol Methods.* 1999, 78(1-2):117-28.

Wyatt LS, Moss B, Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. *Virology.* 1995, 210(1):202-5.

15

20

SEQUENCE LISTING

25 <110> NVI Nederlands Vaccin Instituut
<120> A Respiratory Syncytial Virus with a genomic deficiency complemented in
trans
<130> P210823 pct
<160> 33
<170> PatentIn version 3.1
30 <210> 1
<211> 15213
<212> DNA
<213> Human respiratory syncytial virus
35 <400> 1
acgagaaaaaa aagtgtcaaa aactaatatc tcgttagtttta gttaatatac atataaacca 60
attagatttg ggtttaaatt tattccttct agatcaaaaat gataattttta ggatttagttc 120
40 actagaagttt attaaaaattt atataattat taattttaaa taactataat tgaatacagt 180
gttagtgtgtt agccatggaa atttttttaa taagatttt gttcatttattt cattatggaa 240
45 gttgtataac aaactacctg tgatttttaat cagttttta agttcattgg ttgtcaagct 300

	gtttaacaat tcacttagat gaggatatgt agattctacc atatataaaat gattatagtt	360
5	taattctgtt gatctgaaat taaaacatg attgaaccac tttaagatgt tcatgtgcctt	420
	atgatttata agtttattgc tgaaaacttc attacgtcca gctatagaat aagatagttat	480
	atctccacta acaacactct ttagttaga caatgcagta ttaattcctt tttttgttat	540
10	agggttaacaa agaaagggttcaaaactttaatatttgcataatagact ctttacgc	600
	cttcttaggc atgatgaaat ttttggttct tgatagtatc aathtagcat tttgtactac	660
15	ataaaatact gggAACACAT ttgcaggacc tattgttaagg actaagtaaa ctccagatcc	720
	ctttaactta ctgcctaagc atacataagt ttttaatata gttatgttgt ctaatttcaa	780
	atcgatatac tcttgagcat gatattttac tattaacgta catttattaa ctgaagaaca	840
20	gtacttgcacat tttcttacat gcttgctcca ctctattata attttattcc agttgactgt	900
	tacaggcaat tcagcatcac agacaaaaag gctgataggt tcagcaaact ttatatgtaa	960
25	ataagaccaa tgaatgttgt tggttgcattc tgtagcagga atggtaaat tttcaccata	1020
	atcaatgttg atatgtccat tgtacagcct taaaaactca attggtaaac tatgatcatt	1080
	acaatcttc agacttctgt aaatatatct tatatcagga tgaagttcca ctactgtacg	1140
30	caataataaa ttcccctgctc cttcacctat gaatgctata caattaggat cttaatttt	1200
	aaggctttt aaaatataact ctataactat tttacaacct gtagaactaa atacaaaatt	1260
35	gaatctatta atatgtgcc aagaagcat gcaataaagt gatgtctat tggtactaa	1320
	agatatttga tgagaagtag tagtgtaaag ttggtagat ttggctgtat tacctgaatg	1380
	atctataatt ttatcaatca caaccgtagg aaataaatta tacaaatctt gtctgctgt	1440
40	attggttcta atcattttag acgatttaat aagcttctta ttagataaca atggtaacat	1500
	tattgagtca acatTTTAC ctatacaata gtcattcagt gtcttttat cattacttt	1560
45	aaccggattt gtttgtat tttcttaggt ttctgggtt ggtatgatata atttgggttga	1620
	attactttct aattcagaat tagcaatcct tatatgttta gttaatagat gaggattatc	1680
	tgagaagttt taattatgt aaaaaagatt agaagtataa aattcatcat tgaattttgt	1740
50	tttattttta atgtatattc tatctatatt tatcaatccc attctaaacaa gatctatata	1800
	agttaatattt gctttcatat gtgtggatg ataatctatg ttaacaaccc aaggccaaac	1860
55	tgtgaattct gctacattaa gacgtttaag aaaccatagt ttgaagctat gacatcctt	1920
	tactctatgt aaacttgcacat cctggctaaag aatgtattt gttctaaaaaa	1980
	taccttagac atagacttcc aataactact gtctattaaat tccaaatcac ataggagatc	2040
60	tgaagtatttcc atatcacact ccagcttgc tctgctgtt ccctttagaa aacacaagag	2100
	atatgtctta taagcattga agaaaactttt caaattaatg aacatatgtt cagttatata	2160
	tccctctccc caatctttt caaaaatacc ttttagaatct ttcataagtt gtataatcag	2220
65	aatccaaatgt ccagctaaat tagtactttaa aatgtaaatg ttatgaaaat agtcagat	2280
	cttatgcgcctt aatattaaat tagaattaac attagatcca gatttttagtg ttttattact	2340

	taagaataat tccacatatt gagtcaaact tattttgtct ggtaaaaaca tatgctgtt	2400
5	ttgtatcact tgtttaact tgtaatatc aacatcacct gtgaatatgg gaggtttcat	2460
	caaatgtatc tcattaagct tggatgag aataattctg ttaggacata cattagtaaa	2520
	ttgttctact actgacatta agctaaggcc aaagcttata cagtttgga atactatatc	2580
10	aatatcttc tcaccatact ttctgttaa tatgcgatta ataggctag tatcaaagtg	2640
	atagttgtt gttctatagg ctggatttga tgcagggat tcacatggc tactactgac	2700
15	tgtaagacga tgcaaatagt taacacttaa atattgtgga aataattttt tggccttctc	2760
	atatgctaac ccaagagttc ctatgctaag ttccctccatg aattcatcct tggtatctat	2820
	agatgcatac acccaatcca attttgcata tagatctatt tgatctctt gtttttttgt	2880
20	taaaacttgt ctattataaa ctggcattgt tttttctct tggtagatg aaccaaccca	2940
	tggtttagtg ggtcctctct caccacgtgt taaaactgttg acattatatt tctctatgat	3000
25	tatgccacta gctatagtgc ttgttgtata tttgatgtcc attgtataca tgatactggg	3060
	tgatgtaca ccaactatata tggataaaga ccaagatctt tctctaacat atttacttaa	3120
	ttcagtaata cttaggttt ccatactcaa tatttctctt ttatctctgt tacaatctaa	3180
30	tggtaatatc cttataagca aagttatgtt ttccctcatc atctcagtgg ctctatcaat	3240
	atctgttaag tctatggcag aagtctttt cagtagtta gttatagatt ttgtaccgg	3300
35	tataagattt actattttct ctgctttata aaagggtaaa ctttcataaa caactcttag	3360
	cccgtaggaa tatgttagtt ctatattttg cataatatca ttaagatcta tctctgttagt	3420
	ggtatagtgt tgcacttt tggagaatatt tttgttgtt gctgtgtca aaacctcagt	3480
40	aactgccagt ctattgattt cactagtaat tttagcttgc ctctcagatc ctaaagcttg	3540
	aggatctctc atcaatgtta caaattcagc attagggttt ttgtcaaacg tgattatgca	3600
45	tgttaagaat ttattcaatc tatcatctga cagatcttga agtttatctt ttaaatcatg	3660
	gtttgtataa taactaagta tgaacacaga gtgaactata gcctctgtga gaaaatcagg	3720
	agttcttcta tagaaaacttc gatataacaa gttggatca ccaccaccaa ataacatggg	3780
50	caaattcata tacaatgtta atgctgtatc aatattatca agattaaaaa aggtttttaa	3840
	gtgttttaga acctttaata tgcctaaata taatttgttg ttacataatg catgattttt	3900
55	tagttgtaaa gcaatttgat tatataacca tacatttcta aatattaaac tgcataatag	3960
	actttcacct ctatattcta attttgtgtt caaactacct atagattcta gactcacttt	4020
	gaaatcatca agtatagtgt ttatccacgg tcccactt aggactttct ttataactagc	4080
60	tgggtaatat acaccgttat gttggatcgt ttactcata aattgcataat ctcttgat	4140
	ataagtctca gttcccttta atttggcc tatgcctgca tactctttt acagtaattt	4200
65	gagactgttt aatgctagca aataatctgc ttgagcatga gtttgacctt ccatgagtct	4260
	gactggtttta cttatatactt ttgattgatt gtcaccatca attaaagcag taatttgagaa	4320
	tttccctttt agagatatta gatctaata tagatatagt tctatggtcc atagtttttg	4380

	acaccaccct tcgataccac ccatatgata tctatataat ccactttgt catctacatt	4440
5	gttaagatct acaaatatgat cccttatata ggggggtgca tgcctatatg tgcattattat	4500
	tgtgacatga ggaatagtt aatgtAACCA ggaaaataga gattgtacac catgcagttc	4560
	atccagtaca tcactacaaa tacatgatgt ttcatatcgaa atgcttgat tgaatttgct	4620
10	gagatctgtg atgatagac acttactaat gtaattgtt taattatcat tgtaacgatt	4680
	tgatttttta cttattcctg ctttcaattc taatatttc tgttagttcta gatcaccata	4740
15	tcttgtaaaga ctttcaggga aaaattgtaa aatgtttca gctatcattt tctctgctaa	4800
	tatttgaact tgtctgaaca ttccctggttt cattgcaaac attctaccta cactgagttc	4860
	tctttcttta cctgtcaatg ataccacatg attagggtt ttaagataac tttgattaac	4920
20	tacacagttg tataaatcac attcattgaa tttgttatct cttaaatagt actctaatac	4980
	tcttcttgat ttatcactct cagagaattt taactttca tgttctatata aattttgtat	5040
25	gtgtgacggc atataatttc tagggaaact agtccatatt aaatttttag gaggtgatata	5100
	agccttatca tttatgatca ttccgagatc cacttttta ggcaatcgaa actcccgata	5160
	gaaacgttgt cctgatagaa caatcaaatac tctttctgta agttccaaca aggaaggata	5220
30	agtgttttgt ttatagtaag ttaaccatct taagggtaaa acaatggcat tccttaaagt	5280
	aggccatctg ttgttaattat ttacaaaccc ttttataatt ctatataataa aggcacctct	5340
35	taacataactc aaactgctta acaagtaaaa tttggtctcg ttgcaattaa cttaacagc	5400
	atccatggct tgtcttcata ctaccattgg gtgtccaaat attctgaaca aaaaatataa	5460
	ttcactcaga ttgttaaggt tattgtcacc tgcaagctta attaattttta ggaacttact	5520
40	taatagaatt atccatctgc catttattat attatcgat actgtcttat ctaataatgt	5580
	atgacataact cttgatagca gattttctg agctttatta gcagcatctg tgatgttgtt	5640
45	gagcataacta ttataaaacc gtttctgaa ttgatctct tctgttatata ttAAAATTAG	5700
	agacataata aatccctcta cctcttttat tatgtagaac ccctcattgt gaaatagttt	5760
	tagtatacaa tctccataaa ggaataattg tgtcaagata acattattga atccacatct	5820
50	taaggcttaag cttttattta atgtgttcaa acagttacta atccatgtaa tcaaacaac	5880
	atttatcta ctaaggctaa tatctttcca tgtcaagaat tgattatagg ttgtcacagt	5940
55	aattcttttg agttccttat gataaaactat acaaccatata tgattcaaaa taaattggaa	6000
	tccattaaga gtatgattat ctatcaatat aaaaccatgg tttttacct cactagatcg	6060
	atactgtgtt aatatgctgt ttaattttgt gtataaaatta aaccaatgtaa ttaaccatgt	6120
60	tggaggatgt tgcatcgAAC acattaattt cttcaagagt gttgtttga ttgtatctt	6180
	ttgttttggta gagtgatttt tgtctgcttt aagatgagat tgattatcct taacagctaa	6240
65	aagtataatca tctttgatta tggttgaat aactgagttg tcttcatactt gtccattgtt	6300
	ggatttaatc ttgtctttt cttaagccc cagtttattc agtatacgat agactttgac	6360
	atcactaatt tctatagctc ttcttattat cttttaagt aaatttagtgg tagtaatctg	6420

	ttctgacgag gtcataactct tgtatgtcat aagtaatgac taaaaatagg taggttcttc	6480
5	tatttttatt tcacccttat gatacttaga tattaaggac tgtgttatat ttagtttctt	6540
	tagatttatg tggtcttata atggattttg tctactaatt aagttggat aatcatttt	6600
	gagataagga ccattgaata tgtaacttcc taaagcatta cattctgaga aagaataaac	6660
10	accttttaaa taactatcag ttagataaaac attagcagaa ttccattaa taatgggatc	6720
	cattttgtcc catagcttga attgttttag ttaatagttt gatgatgtgg taagcattag	6780
15	gattgagtgt tatgacacta atatatataat tgtgtatata tcattcattaa tacctagatg	6840
	ttgttagaaaa ttttgagttt catcaatcaa gtcttgagag gtccaatgga ttccattgaa	6900
	tggttattttt ggtgagtata tatggattt ttgggttgtt tgattgatata atagtgtgtt	6960
20	tttttatttacatagtaa ctctacaact acttggattt agtatggaa ttatactaca	7020
	aggatatttg tcaggtatca tcattttttt tggcatggc gttcgatca ctaacagttt	7080
25	attcttttgg gttattgtatc gttatgtct tggatgtttt caatgtgtt ttgatggttt	7140
	tcttcaatac atctgccggc aatctttta acagatgaat agtttggta ttgttttcc	7200
	tggttgcatttca aatataatgtat atgacagtat tgtacactct tatctgggt gaatttggct	7260
30	cttcattgtc ccttagttt ttgatgtcat cactgtttag ttcagtggagg agtttgccta	7320
	tggcaacaca tgctgattgt ttagttatata tatttttttgc tcctatataa ctctctagca	7380
35	ctccaaactac accgaggggca tactcttctg ttctgtccaa ctctgcagct ccacttattt	7440
	ctgataaagt atctatgtttt ttatccatag acttaagtat tctgttttac ataaaatttt	7500
	gtcttacaag cagtgcattttt ggtggccatt caaaataattt atgactaaaa tggcacctct	7560
40	tgccattcaa gcaatgaccc cgaatttcaa atttgcaagg attccttgcgt gacatatttg	7620
	ccccagttctt tatttttaca aatagtaatgtt taatctggta ttcaattgtt ttatataact	7680
45	ataaaaatagg aatctactta aatagtgtaa gtgagatgggt ttatagatga aagttgtgat	7740
	gaagttcaaaa tttaagaaa atccaatgtat agatgggtt tctatgggtt gatagtgaac	7800
	cattgttataa atatgattttt gttatgtttt tattcagacta ctaaatgcaaa tattgtttat	7860
50	accactcagt tgatccttac ttatgtgtac tgggtgtgtt ctggcccttgc aatataagaag	7920
	cagtccaaact gcaatttaatg ataacaatata tactataatc actataatata tagtagttat	7980
55	catgatattt gtgggtggatt taccaggatt tacattatgt aataattcat ctgattttacg	8040
	aataaaatgtt agactctgggtt taatcttctc attgacttga gatattgtatg catcaaattt	8100
	atcagagggg aacactaatg ggtcatagaa atttattttt ggttcacccctt ttacatagag	8160
60	acttttgcct tcttgcttata ttacataata taatgttata cctacagaca cagtagccac	8220
	ccccttattt gatacataat cacacccgtt agaaaaatgtc tttatgtatcc cacgattttt	8280
65	attggatgtt gtacattttat ttttgccata gcatgacaca atggctccata gagatgtgtat	8340
	aacggagctg cttacatctg ttttttgaatgtt cataatttttgc caatcatattt tgggttgtaa	8400
	tatgtcaatg ttgcagagat ttacactact tggtaatgtt aaactgttca ttgtatcaca	8460

	aaatacccgaa tttgattgaa ctttacatgt ttcagcttgt gggaaagaag atactgatcc	8520
5	tgcattgtca cagtaccatc ctctgtcggt tcttgtaag cagatgtgg acccttcatt	8580
	tgtgttggtt gtacatagtg gggatgtgtg cagttccaa caagggttat ctattacacc	8640
	atatagtggt aattgtacta catatgctaa gacttcctcc tttattatgg acatgataga	8700
10	gtaaaccttgc tgtctaacta tttgaacatt gttggacatt aacttttct gatcatgtt	8760
	tataggcata tcattgatta atgataataa ttcaactatta gttaacatat aagtgcattac	8820
15	agggttagtt acacctgcat tgacactaaa ttccctggta atctctagta gtctgttgg	8880
	cttttgggg aattctatca cagttcaat gtttgatatg ctgcagctt gcttggcac	8940
	aataggtaac aactgtttat ctatatagtt tttgagatct aacactttgc tggtaagac	9000
20	actgactcca tttgataagc tgactacagc cttgtttgtg gatagtagag cacttttgc	9060
	tttggtcact tccccttcta ggtcaagac cttggatacg gcaatgccac tggcgattgc	9120
25	agatccaaca cctaacaaaaa agccaagaaa tcttctttc cttttcttgc ttaatgttac	9180
	attgggtttt ttggcattgt tgagtgtata attcataaat cttggtagtt ctcttctggc	9240
	tcgattgttg gctgctggg tgctttgcat gagcaattgt aattctgtta cagcattttt	9300
30	atatttatct aattcttggtt ttatcaattt taccttagcg tctgttccat tacacttatt	9360
	ttccttgata gtacttaatt ctatagttt aacactagta taccaccag ttcttagagc	9420
35	gctaagatag cccttgctaa ctgcactgca tggattgtg tagaattctt cagtgtgtt	9480
	ttgactggaa gcgaaacaga gtgtgactgc agcaaggatt gtggtaatag cattttttt	9540
	gaggattggc aactccattt ttatggccc catagttgat ttgattctg ttgattttgg	9600
40	tcatggcttt ttgcaataat acgctttta atgactactg gtttggatgtg ttggatggag	9660
	atagagattt tgataggtac tcggatgtg tatagacttg tgaagggttt ggattgcctt	9720
45	cgagggtggg tgagtggaga gtttcctttt gacttgtgtg ttctggattt cctgtgggt	9780
	tggaggtgag cagtgttagtt ctgatgtttt tttgggtgtt gttgatgggtt ggctttctg	9840
	tggcctggg ggttaagtgt tcattgggtt ttgtgggtt aggtttgaga tctttttgg	9900
50	ttgtcttgat ggttgggttt ctgtgggtt tgggtgggtt tttctttcca ggttttttgt	9960
	ttggtattct ttgcagatg gcccagcaag ttggattgtt gtcacatgt ctgcagggtt	10020
55	caaagttgaa cacttcaaag tgaaaatcat tattttgggtt gttttgtggg ttgtttggc	10080
	gttgggggtt ggtgggttg ctgggttgta ttgggtgtt gttgtgttt ttggcttgat	10140
	ctgttgttggaa ttgtgggtt gacttagcac ttgggtgtt gtaagctagt gtgggtgg	10200
60	gttgtgtatgt agtttccggac agattggaga ggctgattcc aagctgggg ttctgggtt	10260
	ggatgtttgg ggttgtgttc ttgtatgtt gttgtgtt gcaattata agtgaagttt	10320
65	gtgtgacttt gtgggttgcc gaggctatga atatgatggc tgcaattata agtgaagttt	10380
	agattatcat tgccaaaata gataatgtga ttgtgtctt agatttaaga tttaacttgc	10440
	ataaggcacga tgatatgaat aatagatgtat tgagagtgtc ccaagtcctt tctagtgtct	10500

	tggcggcgcg	ttggtccttg	gtttggaca	tgttgcatt	tgcggcaatg	ttgttgttgg	10560
5	tcttaatatt	ttagttcatt	gttatgacta	tttctaatt	aactacttta	tggtatacat	10620
	gatggcttgc	atggtgagac	gttgcgttgg	ttttgtgaag	aggtgagggt	agttcactta	10680
	caaatgcaag	gttactgttt	ttagctatca	gattggtgaa	tgctatgtat	tgactcgagc	10740
10	tcttggtagc	tcaaagggtt	tgttatggaa	tatgttatat	tcgcagagtt	tgttttagtat	10800
	tgcaatcatg	atggagatta	tgatttagcaa	agagattatt	gttgcattca	tgtgtattag	10860
15	tgtaaagtaa	ggccagaatt	tgcttgagaa	ttcttattgtt	atggatgtat	tttccattgg	10920
	ttgattttgt	ctaatgtgtt	gactagtcta	tgttgacaga	tgttgattgc	agttggattc	10980
	ctctcaatga	ttatggccc	catgtggatt	ttttattaaac	ttatgttgc	actggatctg	11040
20	atgaacaatg	acttgggatg	atctgagact	cctgatgagt	tttgcattgt	tgttgacc	11100
	acaaagggtt	ggtgattacg	attgtgaagt	gaagaatgta	ggtagaaaagt	ttgttatgaat	11160
25	caactcactg	atgttagagga	aaaaggttaa	tcttccatgg	gtttgattgc	aaatcggtta	11220
	gctgtgtgc	tccaatttgc	tgttacataa	tatataacttt	ctttttctaa	gtaagctcca	11280
	agatctacta	tgaattgact	ttgtggcttt	atgtatttga	atgccttgc	gttgcagtc	11340
30	actgtgatga	ctaacagtaa	tcctgagtaa	gggatgattt	ttgcatttgc	aatagcattt	11400
	ttgaattcag	ttgttgttat	attttcaagt	gtgttcagat	ctttatttct	gacactgatg	11460
35	gatctcagg	atgttggat	tatgactttt	tttgcattgt	ctatatttc	aaattcacat	11520
	aaagcaatga	tgtcatgtgt	ttgggttgagt	gttttcata	tgagatcttt	aactgttagtt	11580
	aacatatttt	ttgatttttag	gcatgttgc	ctgcattgc	taatttcaca	gggtgtggtt	11640
40	acatcatatg	ccagcttgct	tcttcattcc	aaggacacat	tggcacatat	ggtaaatttg	11700
	ctgggcattt	gctgtgtgc	tgcacttctt	gagtttatca	tgactctaa	tgttgttccc	11760
45	ttgggtgtgg	atatttgc	caactgtata	ttgacattgg	ctagttctt	tataagtaaa	11820
	tctgctggca	tggatgattt	gaacatgggc	accatatttgc	taagtgtatc	aggatcatcg	11880
	tcttttctt	ggacattgtt	ttgaacacgca	gctgtgtatg	tggagccctc	gtgaagtttgc	11940
50	ttcacgtatg	tttccatatt	tgcggcatct	ttttttgtaa	ctatgtatc	gattttttcc	12000
	gggtggctag	ttttggatttgc	gttgcattttgc	ttttttgtct	gttgcataat	cgccaaatgg	12060
55	atgtttgggtt	ggatgggtga	atgggtttgt	ttgttagtct	tctattgtat	tgttgttttg	12120
	atgtgcagat	aggttagctaa	tcagaaatct	tcaagtgtata	gatcattgtc	actatcattc	12180
	ccttccaaca	ggttgttcaa	tttttctgat	gttggattga	gagacacttc	atctgtatgt	12240
60	tcttttgc	tcttttca	ttcctcattc	ctgagtc	ccatgttgc	tagtctgtca	12300
	ttggtcattt	atgcttcagt	tctgatttttgc	tctatcattt	cttctttaaa	accaaccatgt	12360
65	gcatctctt	taccatcccc	agcagatgtt	ggtcctgcac	tgcgtactac	taatgtgtga	12420
	agcattccca	gtatttcact	taatttctca	tcaatccat	ctaatttgc	tgttatatttgc	12480
	tcgtttgtct	ggtcattaaat	ttcttcataat	gaatagctat	attcttcttc	attgttatca	12540

	aatgtttcta tggtttcttt gtatagtttt gaaaaggat tatcacttgg ctagggct 12600
5	tctttgaaac ttactagagg tttctttga taattggct tgccctac agtatcatct 12660
	gtctcattta ttgggttat aatgggtaa ttgtatgtt tagggcttc ttgggtact 12720
	tctatatcta ttgagtgac agatatgata ctatctttt tcttggatc ttgggtat 12780
10	gtgaatttgc cctttattga ttcttaggaat ttggtggtc tggtttgc atcttctcca 12840
	tggaattcag gagcaaactt ttccatgtatg ttttatttgc cccattttt ttattaactc 12900
15	aaagctctac atcattatct tttggattaa gttgtatgtt gatagcctct agttcttctg 12960
	ctgtcaagtc taatacactg tagttaatca caccatttc tttgagttgt tcagcatatg 13020
	ctttgcagc atcatataga tcttgattcc ttggtgtacc tctgtattct cccattatgc 13080
20	ctaggccagc agcattgcct aatactacac tagagaagt aggaaattga gtcaaagata 13140
	ataatgatgc ttttgggttgc ttcaatatat ggtagaatcc tgcttctcca cccaaatttt 13200
25	ggccatattt atacacctcc acaacctgtt ccatttctgc ttgcacacta gcgtgtccta 13260
	acataatatt tttactgtat tttgctaaga ccccccaccg taacatcaact tgccctgcac 13320
	cataggcatt cataaacaat cctgcaaaga tcccttcaac tctactgcca cctctggtag 13380
30	aagattgtgc tataccaaaa tgaacaaaaa catctataaa gtgaggatat tttcaaaaca 13440
	cttcatagaa gctgttgct atatccttgg gtagtaagcc tttataacgt ttcatttcat 13500
35	tttttaagac attattagct ctccataatca cagctgttaag accagatcta tcccctgctg 13560
	ctaatttggt tattactaat gccgctatac ataatattat catccacaa tcaggagagt 13620
	catgcctgta ttctggagcc acctctccca ttcttttag cattttttg taggattttc 13680
40	tagattctat ctcaatgttg atttgaattt cagttgttaa gcttgctaat gttaacactt 13740
	caaatttcat ttctttccca ttaatgtctt gacgatgtgt tgttacatcc actccatttgc 13800
45	ctttaacatg atatcccgca tctttgagta tttttatggt gtcttctctt cctaattctag 13860
	acatagcata taacataacct attaacccag tgaattttatg attagcatct tctgtgatta 13920
	atagcatgcc acatagctt tgatgtgtt tctgcacatc ataattagga gtgtcaatgc 13980
50	tatctcctgt gctccgttgg atagtgtatt tgctggatga cagaagttga tctttgttga 14040
	gtgtatcatt caacttgact ttgctaagag ccattttgtt atttgccccca tctttcatct 14100
55	tatgtctctc cttaaatttta aattactata attttcaggc tccatttggc ctatggagtg 14160
	tgattgtgca tgaagttatt atttcagatt gtttgaatct tgttttgaaa ttcatggatt 14220
	gagatcatac ttgtatattta tgggtgtgtg cttagtaggc ttaatgccaa tgcattctaa 14280
60	gaacccatca tgattgataa atattggcat agggaaagtgc ccatttttg tttgttattc 14340
	agtatatttt ttatatttag tgcttccac tttgtcaat agttcattt catagttgac 14400
65	caggaatgta aatgtggcct gtcttcatc aagtttctc actatgcatt catgatttat 14460
	caagtatata aatctatgtg ttatgtgtc tctgggtttagt gatgttattta tagtctcaag 14520
	tgacaatggc ctcattgtcag tgatcatcag tctttgttgg gttgtatcat tttgtgttgc 14580

	gtccatggtt gggtcagctt agttgattta tttgc(ccat ttttatcttc tgtcaagttt 14640
5	tatattaact aatggtgtta gtgacattga tttgcttagtt gatatttttataaattttatg 14700
	gattaaggc tc aaatccaagt aattcagata attgattcat ataattggc attggttgaat 14760
	cacttagttt tttggagaat ttaatttcac aattgtcattc tattaggcca ttaggttgag 14820
10	agcaatgcgt taattccatc atttccata tataacctcc attttgcata actggcattg 14880
	ttgtgaagtt ggatttact acaatattat tattaggca aatatcacta cttgtataaa 14940
15	catgcacaaa tacaatgccatc ttcaattaa ttgtatgtat aactgcctt gccaaagcat 15000
	tagttaactg tattaatttg tcagtatagc atgttatttt taacaatgct acttcatcat 15060
	tgtcaaacaa attttgcata ctaacttttca tcaacttcaa tgagttgtg cccatctcta 15120
20	acccaaaggag taaaatttaa gtggtactta tcaaattctt atttgc(cca tttttttgg 15180
	ttacgcaagt ttgttgtacg catttttcg cgt 15213
25	<210> 2 <211> 47 <212> DNA <213> Artificial <400> 2 aattggtacc taatacgact cactataggg acgagaaaaa aagtgtc 47
30	<210> 3 <211> 27 <212> DNA <213> Artificial <400> 3 ttaaacgcgt catcaaacta ttaactc 27
35	<210> 4 <211> 29 <212> DNA <213> Artificial <400> 4 aattacgcgt taaggcattag gattgagtg 29
40	<210> 5 <211> 33 <212> DNA <213> Artificial <400> 5 ttaaggatcc gcgcgcattt attgcaaaaaa gcc 33
45	<210> 6 <211> 27 <212> DNA <213> Artificial <400> 6 aattgcgcgc tttttatga ctactgg 2
50	<210> 7 <211> 38 <212> DNA <213> Artificial <400> 7 ttaaggatcc gtacgttggg gcaaatgcaa acatgtcc 38
55	<210> 8 <211> 28 <212> DNA

	<213> Artificial	
	<400> 8	28
	ttaaccggg gcaaataaaa catcatgg	
5	<210> 9	
	<211> 46	
	<212> DNA	
	<213> Artificial	
	<400> 9	
10	aattcgtacg tattgttagt cttaatatct tagttcatgg ttatga	46
	<210> 10	
	<211> 32	
	<212> DNA	
15	<213> Artificial	
	<400> 10	
	aattcccgaa attttttta ttaactcaaa gc	32
20	<210> 11	
	<211> 43	
	<212> DNA	
	<213> Artificial	
	<400> 11	
	ttaaacctgg taagatgaaa gatggggcaa atacaaaaat ggc	43
25	<210> 12	
	<211> 38	
	<212> DNA	
	<213> Artificial	
30	<400> 12	
	aattggatcc accaggcttc tccttaattt taaattac	38
	<210> 13	
	<211> 65	
35	<212> DNA	
	<213> Artificial	
	<400> 13	
	aattcttaag ggaccgcgag gaggtggaga tgccatgccg acccacgcga aaaaatgcgt	60
	acaac	65
40	<210> 14	
	<211> 28	
	<212> DNA	
	<213> Artificial	
45	<400> 14	
	gtccgacctg ggcatacgaa ggaggacg	28
	<210> 15	
	<211> 26	
50	<212> DNA	
	<213> Artificial	
	<400> 15	
	acgtcctcct tcggatgcc aggtcg	26
55	<210> 16	
	<211> 68	
	<212> DNA	
	<213> Artificial	
	<400> 16	
60	tcgtccactc ggatggctaa gggataacc cttggggcc tctaaacggg tcttgagggg	60
	ttttttgc	68
	<210> 17	
	<211> 71	
65	<212> DNA	
	<213> Artificial	
	<400> 17	
	ggccgcaaaa aaccctcaa gaccgttta gaggccccaa ggggttattc ccttagccat	60

	ccgagtggac g	71
5	<210> 18 <211> 29 <212> DNA <213> Artificial <400> 18 ttaactcgag ttattcatta tgaaagttg	29
10	<210> 19 <211> 27 <212> DNA <213> Artificial <400> 19	
15	aattggtacc gggacaaaaat ggatccc <210> 20 <211> 27 <212> DNA <213> Artificial <400> 20 ttaatctaga ttgttaactat attatag	27
20		27
25	<210> 21 <211> 31 <212> DNA <213> Artificial <400> 21 aattggatcc gggcaaata aatcatcatg g	31
30	<210> 22 <211> 29 <212> DNA <213> Artificial <400> 22	
35	aattggatcc gggcaaata caagatggc <210> 23 <211> 31 <212> DNA <213> Artificial <400> 23 ttaactcgag attaactcaa agctctacat c	29
40		31
45	<210> 24 <211> 31 <212> DNA <213> Artificial <400> 24	
50	aattggatcc gggcaaata tgtcacgaag g <210> 25 <211> 34 <212> DNA <213> Artificial <400> 25 ttaatctaga tcaggttagta tcattattt tggc	31
55		34
60	<210> 26 <211> 26 <212> DNA <213> Artificial <400> 26 ttaatctaga agtaactact ggcgtg	
65	<210> 27 <211> 44 <212> DNA	26

<213> Artificial
<400> 27
aattggatcc gggcaata caaacatgtc caaaaacaag gacc 44

5 <210> 28
<211> 32
<212> DNA
<213> Artificial
<400> 28

10 aattccatgg ggtccaaaac caaggaccaa cg 32

<210> 29
<211> 31
<212> DNA

15 <213> Artificial
<400> 29
aaaagtatac ttaatgtgat ttgtgctata g 31

<210> 30
<211> 44
<212> DNA
<213> Artificial
<400> 30

20 ttttgtatac tggcagctat aatctcaact tcacttataa ttgc 44

<210> 31
<211> 27
<212> DNA

25 <213> Artificial
<400> 31
aatttctaga ttttaatga ctactgg 27

<210> 32
<211> 31
<212> DNA

30 <213> Artificial
<400> 32
ttaatctaga cgttacgcga acgcgaagtc c 31

<210> 33
<211> 41
<212> DNA

35 <213> Artificial
<400> 33
aattaagctt accatggaca cgattaacat cgctaagaac g 41